Depression Clinical Trial
Official title:
Safety, Tolerance and Pharmacokinetics of Hydrochloric Acid (R) -Ketamine Nasal Spray in Healthy Subjects: A Randomized, Double Blind, Placebo-Controlled Phase I Clinical Trial
Verified date | June 2022 |
Source | Jiangsu HengRui Medicine Co., Ltd. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The study is being conducted to evaluate the safety and pharmacokinetics of HR071603 in healthy subjects.
Status | Completed |
Enrollment | 50 |
Est. completion date | June 1, 2021 |
Est. primary completion date | June 1, 2021 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Male |
Age group | 18 Years to 45 Years |
Eligibility | Inclusion Criteria: 1. Obtain informed consent prior to the start of any activity related to the trial, and have a thorough understanding of the purpose and meaning of the trial and be willing to comply with the protocol; 2. Healthy males aged between 18 and 45 (including both ends); 3. Weight = 50kg, body mass index (BMI) in the range of 18.5 ~ 23.9 (including both ends); 4. During the trial and within 30 days after the administration, willing to take contraceptive measures and ensure that no sperm is donated. Exclusion Criteria: 1. A subject considered by the investigator to be unsuitable for nasal spray administration; 2. Allergic to any component of the study drug; 3. The underlying disease is not suitable for participation in the trial; 4. 12-lead ECG results in the screening period are abnormal and clinically significant 5. Liver dysfunction; 6. Serum creatinine > 1.2 × ULN during screening period; 7. Screening for infectious diseases screening hepatitis B surface antigen (HBsAg), hepatitis C antibody (HCVAb), syphilis antibody, human immunodeficiency virus (HIV) antibody test positive; 8. Subject has been thoroughly examined, and the results are abnormal and clinically significant; 9. Major operations were performed within 3 months before the screening period. 10. Donate whole blood/plasma within one month before the screening period, or donate whole blood/plasma more than 400 ml within three months before the screening period; 11. Positive urine drug test; 12. The alcohol breath test is positive; or the average daily intake of alcohol exceeds 15g; 13. Nicotine test is positive; 14. History of drug abuse or alcohol abuse; 15. In the past three months, over five cups of coffee or tea per day were consumed in an average; 16. Any prescription drugs, over-the-counter drugs and health products were used within 2 weeks before screening. 17. Participated in clinical trials of any drug or medical device within 3 months before screening ; 18. Any other medical or psychological condition, which in the opinion of the Investigator, might create undue risk to the participant or interfere with the participant's ability to comply with the protocol requirements, or to complete the study. |
Country | Name | City | State |
---|---|---|---|
China | Beijing AnDing hospital affiliated to Capital Medical University | Beijing | Beijing |
Lead Sponsor | Collaborator |
---|---|
Jiangsu HengRui Medicine Co., Ltd. |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Incidence of Adverse Events (Safety and Tolerability) | Pre-dose to Day8 | ||
Secondary | Assessment of PK parameter-Area under drug-time curve (AUC) | Pre-dose to Day2 | ||
Secondary | Assessment of PK parameter-peak time (Tmax) | Pre-dose to Day2 | ||
Secondary | Assessment of PK parameter-peak concentration (Cmax) | Pre-dose to Day2 | ||
Secondary | Assessment of PK parameter-half-life (t1/2) | Pre-dose to Day2 | ||
Secondary | Assessment of PK parameter-apparent clearance rate (CL/F) | Pre-dose to Day2 | ||
Secondary | Assessment of PK parameter-apparent distribution volume (Vz/F) | Pre-dose to Day2 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05777044 -
The Effect of Hatha Yoga on Mental Health
|
N/A | |
Recruiting |
NCT04977232 -
Adjunctive Game Intervention for Anhedonia in MDD Patients
|
N/A | |
Recruiting |
NCT04680611 -
Severe Asthma, MepolizumaB and Affect: SAMBA Study
|
||
Recruiting |
NCT04043052 -
Mobile Technologies and Post-stroke Depression
|
N/A | |
Completed |
NCT04512768 -
Treating Comorbid Insomnia in Transdiagnostic Internet-Delivered Cognitive Behaviour Therapy
|
N/A | |
Recruiting |
NCT03207828 -
Testing Interventions for Patients With Fibromyalgia and Depression
|
N/A | |
Completed |
NCT04617015 -
Defining and Treating Depression-related Asthma
|
Early Phase 1 | |
Recruiting |
NCT06011681 -
The Rapid Diagnosis of MCI and Depression in Patients Ages 60 and Over
|
||
Completed |
NCT04476446 -
An Expanded Access Protocol for Esketamine Treatment in Participants With Treatment Resistant Depression (TRD) Who do Not Have Other Treatment Alternatives
|
Phase 3 | |
Recruiting |
NCT02783430 -
Evaluation of the Initial Prescription of Ketamine and Milnacipran in Depression in Patients With a Progressive Disease
|
Phase 2/Phase 3 | |
Recruiting |
NCT05563805 -
Exploring Virtual Reality Adventure Training Exergaming
|
N/A | |
Completed |
NCT04598165 -
Mobile WACh NEO: Mobile Solutions for Neonatal Health and Maternal Support
|
N/A | |
Completed |
NCT03457714 -
Guided Internet Delivered Cognitive-Behaviour Therapy for Persons With Spinal Cord Injury: A Feasibility Trial
|
||
Recruiting |
NCT05956912 -
Implementing Group Metacognitive Therapy in Cardiac Rehabilitation Services (PATHWAY-Beacons)
|
||
Completed |
NCT05588622 -
Meru Health Program for Cancer Patients With Depression and Anxiety
|
N/A | |
Recruiting |
NCT05234476 -
Behavioral Activation Plus Savoring for University Students
|
N/A | |
Active, not recruiting |
NCT05006976 -
A Naturalistic Trial of Nudging Clinicians in the Norwegian Sickness Absence Clinic. The NSAC Nudge Study
|
N/A | |
Enrolling by invitation |
NCT03276585 -
Night in Japan Home Sleep Monitoring Study
|
||
Completed |
NCT03167372 -
Pilot Comparison of N-of-1 Trials of Light Therapy
|
N/A | |
Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A |